GSK plc
GSKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, GSK plc (GSK) is listed under Drug Manufacturers - General. At a $99.92B market cap, GSK plc ranks as a large-cap company within healthcare. It operates through Commercial Operations and Total R&D segments.
Market Cap
$99.92B
Beta
0.29
P/E (TTM)
15.69
P/E (Fwd)
10.02
EPS (TTM)
$3.18
EPS (Fwd)
$4.98
ROE
33.4%
ROA
10.0%
Cash
$3.11B
Total Debt
$18.29B
Free CF
$3.48B
52W Change
22.3%
Annual Financials
Cash vs Debt
Where GSK stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, GSK finished 4.63% below its 150-day moving average ($52.69) and 2.14% below its 200-day moving average ($51.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GSK overbought or oversold?
At the September 1, 2026 close, GSK's RSI(14) was 49.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $3.11B in cash, though total debt stands at $18.29B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $3.48B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 33.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.0% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $29.32B to $32.67B.
The relatively low beta of 0.29 suggests GSK is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for GSK plc and its sector.